• Mashup Score: 3

    JavaScript is used in a variety of ways to improve your browsing experience, such as validating and executing form submissions and allowing interactive content. Below, we have provided simple instructions for enabling JavaScript in the most popular web browsers. To determine your browser version, click on Help in the menu bar of your browser and then select About. Once you have enabled…

    Tweet Tweets with this article
    • Jeff Bezos awards Dolly Parton $100 million to give to whatever charities she chooses - https://t.co/wlfr9QzqqV #MondayMotivation #HLTH2022

  • Mashup Score: 1
    Teenage Brains - 1 year(s) ago

    Moody. Impulsive. Maddening. Why do teenagers act the way they do? Viewed through the eyes of evolution, their most exasperating traits may be the key to success as adults.

    Tweet Tweets with this article
    • RT @elenacarstoiu: Read if you have a #teenager around and want to keep calm šŸ˜… https://t.co/PiHYbBfvBv #MondayMotivation #teenaged

  • Mashup Score: 3
    Tweet Tweets with this article
    • Teamwork makes Mondays so much easier! Check out this weekā€™s motivational quotešŸ‘‡šŸ» & donā€™t forget to share some of your favorites. @SWexner @juliomayol @SyedAAhmad5 @TsengJennifer @SaraSaeidi92 @nlavellaneda @hayfarani #SoMe4Surgery #MondayMotivation https://t.co/wKeBUeLb7F

  • Mashup Score: 10

    Results from the precision oncology ARROW trial identify the RET receptor tyrosine kinase as a tissue-agnostic target and the drug pralsetinibā€™s potential as a well-tolerated treatment option with rapid, robust and durable anti-tumor activity in patients with diverse RET fusionā€“positive solid tumors.

    Tweet Tweets with this article
    • Pan-cancer efficacy of pralsetinib in patients with RET fusionā€“positive solid tumors from the phase 1/2 ARROW trial https://t.co/jGmz9d2Z4T

    • ā­ļøOut now our paper in @NatureMedicine open access version for your quick #MondayMotivation in #precisionmedicine šŸ‘‰ Pan-cancer efficacy of pralsetinib in patients with RET fusionā€“positive solid tumors from the phase 1/2 ARROW trial @OncoAlert @curijoey https://t.co/jGmz9d2rfl https://t.co/La1VKfZald